Tonghua Dongbao released its 2026 interim report on August 25, 2026. Total operating revenue was 1.553 billion yuan, net profit attributable to the parent company was 296 million yuan, and net cash inflow from operating activities was 533 million yuan. The latest asset-liability ratio was 12.95 percent, up 0.69 percentage points from the previous quarter. The latest gross margin was 70.79 percent, down 0.83 percentage points from the previous quarter and down 0.66 percentage points from the same period last year. The latest return on equity was 4.33 percent, and diluted earnings per share was 0.15 yuan. The latest total asset turnover was 0.20 times, inventory turnover was 0.66 times, the number of shareholders was 114,700, and the top ten shareholders held 939 million shares, accounting for 47.96 percent of total share capital.
Tonghua Dongbao Pharmaceutical Co LtdInterim report shows net profit of 296 million yuan, but no comparative expectations or market reaction provided.
